Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Eleven Biotherapeutics Inc. ($EBIO) announced that its pivotal Phase 3 clinical trial assessing Vicinium in non-muscle invasive bladder cancer exceeded 50% enrollment. The company also said that the trial will proceed without modification as recommended by the independent Data and Safety Monitoring Board.  The markets reacted positively to the news and the stock jumped over 5 percent in the previous trading session, trimming its Year to Date losses to 24 percent. The stock price is up 9 percent in the past 12 months.
Vicinium is a single protein anti-epithelial cell adhesion molecule (anti-EpCAM) antibody fragment fused with Pseudomonas Exotoxin A (ETA) that is designed to specifically target and deliver a potent anti-cancer payload directly into tumor cells.

XBiotech ($XBIT) announced the results of a European Phase 3 study evaluating MABp1 for the treatment of patients with symptomatic refractory metastatic colorectal cancer, sending its stock price up 26 percent. The results showed that 40% of patients treated with MABp1 achieved the primary endpoint compared to 23% for placebo (p=0.003). 42% of patients treated with MABp1 experienced stable disease compared to 12% for others. Median overall survival in the test group was 11.7 months vs. 5.7 months in patients who did not receive MABp1.
The company stock had lost 35 percent of its value in the past 12 months while its YTD loss stood at 8 percent.

 

BioPharmX ($BPMX) announced positive  results from a Phase 2b clinical trial assessing the 2% formulation of BPX-01 for the treatment of acne vulgaris. The were no serious drug-related adverse events observed. The data showed treatment with BPX-01 reduced the number of inflammatory lesions by 59% compared to 44% for vehicle (placebo) at week 12, a statistically significant result.

Biogen ($BIIB) announced receiving the European Commission’s approval for its marketing application for SPINRAZA (nusinersen) for the treatment of 5q spinal muscular atrophy, the most common form of the disorder. The approval triggers a $50 million milestone payment to licensor Ionis Pharmaceuticals.

Protalix BioTherapeutics ($PLX) announced receiving the FDA approval for its conversion of its Carmiel, Israel manufacturing site to a multi-product facility. The approval will enable the company to accommodate all of its current and expected commercial and clinical needs, including Fabry candidate PRX-102.

BioMarin Pharmaceutical ($BMRN) announced receiving the European Commission’s approval for its  Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 in patients of all ages. Brineura is an enzyme replacement therapy that is directly administered to the brain.

 
Tenet Healthcare ($THC) announced amending its multiyear in-network access agreement with Humana ($HUM). The deals pertains to phasing all of Tenet's hospitals, hospital-affiliated outpatient centers and clinics back into Humana's network. Pursuant to amendment, all of Humana's members who have commercial insurance, Medicare, Medicaid or personal insurance bought on an exchange will be considered in-network with all Tenet providers.

Inovio Pharmaceuticals ($INO) announced its collaboration with Roche’s Genentech for a clinical trial assessing the combination of INO-5401, a T cell-activating immunotherapy, and Tecentriq (atezolizumab) in patients with advanced urothelial carcinoma (bladder cancer).

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Jefferies Group LLC
Reiterates
Abeona Therapeutics (ABEO)
Buy
$11.00
High
KeyCorp
Reiterates
Acadia Healthcare Company (ACHC)
Overweight
$51.00
Low
Jefferies Group LLC
Set Price Target
Acadia Healthcare Company (ACHC)
Buy
$55.00
Low
Oppenheimer Holdings
Set Price Target
Agios Pharmaceuticals (AGIO)
Buy
$75.00
Low
Jefferies Group LLC
Reiterates
Align Technology (ALGN)
Buy
$150.00
Low
Jefferies Group LLC
Reiterates
Alere (ALR)
Hold
$51.00
Medium
Barclays PLC
Reiterates
AMAG Pharmaceuticals (AMAG)
Equal Weight
$25.00 -> $20.00
Low
HC Wainwright
Reiterates
Amarin Co. plc (AMRN)
Buy
$10.00
N/A
Maxim Group
Reiterates
Bioline RX Ltd (BLRX)
Buy
$3.00
Low

Gainers (% price change) Last Trade Change Mkt Cap
Kindred Healthcare, Inc. KND 10.75 +0.95 (9.69%) 925.28M
Natus Medical Inc BABY 36.45 +2.55 (7.52%) 1.20B
Endocyte, Inc. ECYT 2.73 +0.18 (7.06%) 108.30M
Clovis Oncology Inc CLVS 55.21 +3.55 (6.87%) 2.44B
Fluidigm Corporation FLDM 4.84 +0.31 (6.84%) 139.63M
Losers (% price change)
Insys Therapeutics Inc INSY 14.19 -0.51 (-3.47%) 1.03B
China Cord Blood Corp CO 8.35 -0.15 (-1.76%) 979.93M
Rockwell Medical Inc RMTI 7.06 -0.10 (-1.40%) 367.01M
Concord Medical Services CCM 3.64 -0.05 (-1.36%) 161.91M
Compugen Ltd. (USA) CGEN 4.75 -0.05 (-1.04%) 248.65M
Most Actives (dollar volume)
Pfizer Inc. PFE 32.71 +0.06 (0.18%) 197.94B
Johnson & Johnson JNJ 128.78 +0.53 (0.41%) 350.02B
Gilead Sciences, Inc. GILD 64.62 -0.27 (-0.42%) 84.96B
Regeneron Pharmaceuticals REGN 466.02 +6.96 (1.52%) 50.68B
UnitedHealth Group Inc UNH 179.58 +4.40 (2.51%) 171.67B